

## **Product datasheet for SR300710**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## CDC25B Human siRNA Oligo Duplex (Locus ID 994)

**Product data:** 

**Product Type:** siRNA Oligo Duplexes

Purity: HPLC purified

Quality Control: Tested by ESI-MS

Sequences: Available with shipment

**Stability:** One year from date of shipment when stored at -20°C.

# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

**Note:** Single siRNA duplex (10nmol) can be ordered.

RefSeq: NM 001287516, NM 001287517, NM 001287518, NM 001287519, NM 001287520,

NM 001287522, NM 001287524, NM 004358, NM 021872, NM 021873, NM 021874,

NM 212530, NR 136335, NR 136336

UniProt ID: P30305

Components: CDC25B (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 994)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

**Summary:** CDC25B is a member of the CDC25 family of phosphatases. CDC25B activates the cyclin

dependent kinase CDC2 by removing two phosphate groups and it is required for entry into mitosis. CDC25B shuttles between the nucleus and the cytoplasm due to nuclear localization and nuclear export signals. The protein is nuclear in the M and G1 phases of the cell cycle and moves to the cytoplasm during S and G2. CDC25B has oncogenic properties, although its role in tumor formation has not been determined. Multiple transcript variants for this gene

exist. [provided by RefSeq, Jul 2008]





### CDC25B Human siRNA Oligo Duplex (Locus ID 994) - SR300710

# Performance Guaranteed:

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).